AR076219A1 - Analogos de isoxazol-3 (2h)-ona como agentes terapeuticos - Google Patents
Analogos de isoxazol-3 (2h)-ona como agentes terapeuticosInfo
- Publication number
- AR076219A1 AR076219A1 ARP100101162A ARP100101162A AR076219A1 AR 076219 A1 AR076219 A1 AR 076219A1 AR P100101162 A ARP100101162 A AR P100101162A AR P100101162 A ARP100101162 A AR P100101162A AR 076219 A1 AR076219 A1 AR 076219A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- deuterium
- fluorine
- heteroaryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Gastroenterology & Hepatology (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
La presente se refiere a un compuesto de formula (1) o una sal farmacéuticamente aceptable del mismo, en donde, R1 y R2 son independientemente hidrogeno, deuterio, arilo, heteroarilo, alquilo C1-8, estando opcionalmente sustituidos por R3; R3 es un arilo, heteroarilo, fluor(es), un alquilo C1-6 que contiene uno o más fluor, un alquilo C1-6 que contiene uno o más deuterio, un alquilo C1-6 que contiene hidroxi, estando el heteroarilo opcionalmente sustituido por uno o más halogeno, tal como fluor, uno o más deuterio, un alquilo C1-6, alcoxi C1-6, nitrilo, o R3 es un alquilo C1-6 opcionalmente sustituido por uno o más de los siguientes grupos: COOR4, OCOR4, CONR5R6, NR5COR6, OR4; en donde, R4 es un alquilo C1-10 opcionalmente sustituido por uno o más fluor, deuterio, alcoxi, arilcarboxilato, alquil carboxilato; R5 y R6 se seleccionan independientemente de hidrogeno, alquilo o juntos pueden formar un anillo de carbono de 4 - 8 miembros; o R1 y R2 forman un anillo de carbono de 3 - 10 miembros que opcionalmente comprende O o N y opcionalmente se sustituye por un alquilo o arilo C1-10, heteroarilo opcionalmente sustituido por R3. Composiciones farmacéuticas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16722409P | 2009-04-07 | 2009-04-07 | |
| US17195609P | 2009-04-23 | 2009-04-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR076219A1 true AR076219A1 (es) | 2011-05-26 |
Family
ID=42934883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100101162A AR076219A1 (es) | 2009-04-07 | 2010-04-07 | Analogos de isoxazol-3 (2h)-ona como agentes terapeuticos |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8415378B2 (es) |
| EP (1) | EP2417131A4 (es) |
| JP (1) | JP5711723B2 (es) |
| KR (1) | KR101675607B1 (es) |
| CN (1) | CN102459246B (es) |
| AR (1) | AR076219A1 (es) |
| AU (1) | AU2010235236B2 (es) |
| BR (1) | BRPI1013984A2 (es) |
| CA (1) | CA2757879C (es) |
| CO (1) | CO6440580A2 (es) |
| CU (1) | CU20110190A7 (es) |
| EA (1) | EA020825B1 (es) |
| EC (1) | ECSP11011385A (es) |
| IL (1) | IL215336A0 (es) |
| MX (1) | MX2011010647A (es) |
| NI (1) | NI201100181A (es) |
| SG (1) | SG174463A1 (es) |
| TW (1) | TW201040166A (es) |
| UY (1) | UY32543A (es) |
| WO (1) | WO2010117323A1 (es) |
| ZA (1) | ZA201108119B (es) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110092266A (ko) | 2008-08-04 | 2011-08-17 | 씨에이치디아이 파운데이션, 인코포레이티드 | 소정 키누레닌-3-모노옥시게나아제 억제제, 약학적 조성물, 및 그의 사용 방법 |
| CN102811620B (zh) | 2010-01-25 | 2015-03-25 | Chdi基金会股份有限公司 | 一些犬尿氨酸-3-单加氧酶抑制剂、药物组合物及其使用方法 |
| WO2012047156A1 (en) * | 2010-10-04 | 2012-04-12 | Astrazeneca Ab | Isoxazol-3(2h)-one analogs as plasminogen inhibitors and their use in the treatment of fibrinolysis related diseases |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| EA027451B1 (ru) * | 2011-08-30 | 2017-07-31 | Схди Фаундейшн, Инк. | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и их применение |
| AU2012300246A1 (en) | 2011-08-30 | 2014-03-06 | Chdi Foundation, Inc. | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| US9073881B2 (en) | 2011-09-23 | 2015-07-07 | Hoffmann-La Roche Inc. | Benzoic acid derivatives |
| SG11201408238WA (en) | 2012-06-13 | 2015-01-29 | Incyte Corp | Substituted tricyclic compounds as fgfr inhibitors |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| CN102977050B (zh) * | 2012-11-20 | 2015-04-22 | 浙江工业大学 | 一种2-苯并噻唑二甲缩醛和2-苯并噻唑甲醛的合成方法 |
| CN102977040B (zh) * | 2012-11-20 | 2015-06-03 | 浙江工业大学 | 一种2-喹喔啉基二甲缩醛和2-喹喔啉基甲醛的合成方法 |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| EA035095B1 (ru) | 2013-04-19 | 2020-04-27 | Инсайт Холдингс Корпорейшн | Бициклические гетероциклы в качестве ингибиторов fgfr |
| UY35809A (es) | 2013-11-05 | 2015-05-29 | Bayer Pharma AG | (aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usos |
| SG11201700341PA (en) | 2014-07-17 | 2017-02-27 | Chdi Foundation Inc | Methods and compositions for treating hiv-related disorders |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| CA2966259A1 (en) | 2014-11-03 | 2016-05-12 | Bayer Pharma Aktiengesellschaft | Piperidinylpyrazolopyrimidinones and their use |
| JP2017537935A (ja) | 2014-12-19 | 2017-12-21 | エメリティー ファルマ エービー | 皮膚疾患の処置のための３−（ピペリジン−４−イル）イソキサゾール−３（２ｈ）−オン |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| CR20170390A (es) | 2015-02-20 | 2017-10-23 | Incyte Holdings Corp | Heterociclos biciclicos como inhibidores de fgfr |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| CN104725300A (zh) * | 2015-02-28 | 2015-06-24 | 宁波九胜创新医药科技有限公司 | 一种1-(6-甲基吡啶-3-基)-2-(4-甲磺酰基苯基)乙酮的制备方法 |
| WO2016173948A1 (en) | 2015-04-30 | 2016-11-03 | Bayer Pharma Aktiengesellschaft | Indazolopyrimidinones as fibrinolysis inhibitors |
| CN107459514B (zh) * | 2016-06-06 | 2020-10-23 | 南开大学 | 一类手性哌啶衍生物及其制备方法和用途 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| CN107857725A (zh) * | 2017-12-19 | 2018-03-30 | 苏州艾缇克药物化学有限公司 | 一种2‑氨基吡啶‑4‑甲醇的合成方法 |
| SG11202010636VA (en) | 2018-05-04 | 2020-11-27 | Incyte Corp | Solid forms of an fgfr inhibitor and processes for preparing the same |
| WO2019213506A1 (en) | 2018-05-04 | 2019-11-07 | Incyte Corporation | Salts of an fgfr inhibitor |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CR20220169A (es) | 2019-10-14 | 2022-10-27 | Incyte Corp | Heterociclos bicíclicos como inhibidores de fgfr |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CA3162010A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Derivatives of an fgfr inhibitor |
| JP2023505258A (ja) | 2019-12-04 | 2023-02-08 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式複素環 |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| TWI803177B (zh) * | 2021-02-05 | 2023-05-21 | 大陸商賽諾哈勃藥業（成都）有限公司 | 一種纖維蛋白溶酶抑制劑、其製備方法及應用 |
| CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9408137A (pt) * | 1993-11-24 | 1997-08-12 | Du Pont Merck Pharma | Composto éster de prodroga método de tratamento composição farmacêutica e método de inibição |
| WO2000029406A2 (en) * | 1998-11-18 | 2000-05-25 | Du Pont Pharmaceuticals Company | Novel isoxazoline fibrinogen receptor antagonists |
| US20030207873A1 (en) * | 2002-04-10 | 2003-11-06 | Edmund Harrington | Inhibitors of Src and other protein kinases |
| NZ543287A (en) * | 2003-04-15 | 2008-08-29 | Merck & Co Inc | Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors |
| US7598243B2 (en) * | 2003-04-17 | 2009-10-06 | Merck & Co., Inc. | Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity |
| CN101328173B (zh) * | 2008-07-31 | 2010-12-15 | 石药集团欧意药业有限公司 | 一种制备6-氟-3-(4-哌啶基)-1,2-苯并异噁唑盐酸盐的方法 |
-
2010
- 2010-04-06 MX MX2011010647A patent/MX2011010647A/es active IP Right Grant
- 2010-04-06 KR KR1020117026407A patent/KR101675607B1/ko active IP Right Grant
- 2010-04-06 CA CA2757879A patent/CA2757879C/en not_active Expired - Fee Related
- 2010-04-06 UY UY0001032543A patent/UY32543A/es not_active Application Discontinuation
- 2010-04-06 TW TW099110636A patent/TW201040166A/zh unknown
- 2010-04-06 SG SG2011067568A patent/SG174463A1/en unknown
- 2010-04-06 AU AU2010235236A patent/AU2010235236B2/en not_active Ceased
- 2010-04-06 JP JP2012504655A patent/JP5711723B2/ja not_active Expired - Fee Related
- 2010-04-06 EP EP10761933.0A patent/EP2417131A4/en not_active Withdrawn
- 2010-04-06 WO PCT/SE2010/050375 patent/WO2010117323A1/en active Application Filing
- 2010-04-06 CN CN201080025847.5A patent/CN102459246B/zh not_active Expired - Fee Related
- 2010-04-06 EA EA201190237A patent/EA020825B1/ru not_active IP Right Cessation
- 2010-04-06 BR BRPI1013984A patent/BRPI1013984A2/pt not_active Application Discontinuation
- 2010-04-06 US US12/755,010 patent/US8415378B2/en not_active Expired - Fee Related
- 2010-04-07 AR ARP100101162A patent/AR076219A1/es unknown
-
2011
- 2011-09-22 IL IL215336A patent/IL215336A0/en unknown
- 2011-10-06 CO CO11132448A patent/CO6440580A2/es not_active Application Discontinuation
- 2011-10-07 CU CU20110190A patent/CU20110190A7/es unknown
- 2011-10-07 EC EC2011011385A patent/ECSP11011385A/es unknown
- 2011-10-07 NI NI201100181A patent/NI201100181A/es unknown
- 2011-11-04 ZA ZA2011/08119A patent/ZA201108119B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NI201100181A (es) | 2012-06-14 |
| CN102459246B (zh) | 2014-05-07 |
| TW201040166A (en) | 2010-11-16 |
| EA201190237A1 (ru) | 2012-04-30 |
| WO2010117323A8 (en) | 2010-11-18 |
| BRPI1013984A2 (pt) | 2018-06-19 |
| US8415378B2 (en) | 2013-04-09 |
| SG174463A1 (en) | 2011-10-28 |
| JP2012522836A (ja) | 2012-09-27 |
| AU2010235236B2 (en) | 2013-10-24 |
| WO2010117323A1 (en) | 2010-10-14 |
| CA2757879A1 (en) | 2010-10-14 |
| US20100261755A1 (en) | 2010-10-14 |
| JP5711723B2 (ja) | 2015-05-07 |
| AU2010235236A1 (en) | 2011-10-20 |
| KR101675607B1 (ko) | 2016-11-11 |
| EP2417131A4 (en) | 2014-08-27 |
| MX2011010647A (es) | 2012-02-21 |
| ZA201108119B (en) | 2012-07-25 |
| CN102459246A (zh) | 2012-05-16 |
| UY32543A (es) | 2010-11-30 |
| ECSP11011385A (es) | 2011-11-30 |
| EP2417131A1 (en) | 2012-02-15 |
| CA2757879C (en) | 2017-06-06 |
| CO6440580A2 (es) | 2012-05-15 |
| KR20120034611A (ko) | 2012-04-12 |
| EA020825B1 (ru) | 2015-02-27 |
| CU20110190A7 (es) | 2012-02-15 |
| IL215336A0 (en) | 2011-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR076219A1 (es) | Analogos de isoxazol-3 (2h)-ona como agentes terapeuticos | |
| PE20211655A1 (es) | Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1 | |
| MX2015015893A (es) | 2-fenilimidazo[1,2-a]pirimidinas como agentes formadores de imagen. | |
| PE20130155A1 (es) | Derivados de ariletinilo | |
| AR105845A1 (es) | Compuestos de heteroarilo bicíclicos fusionados como moduladores de la función irak4 | |
| AR085327A1 (es) | Inhibidores del virus de la hepatitis c | |
| AR078152A1 (es) | Compuestos heterociclicos, utiles para el tratamiento de hcv y composiciones farmaceuticas que los comprenden | |
| AR094262A1 (es) | Compuestos antivirales para el tratamiento de la hepatitis c | |
| AR070828A1 (es) | Derivados de azetidina y ciclobutano como inhibidores de jak | |
| AR070459A1 (es) | Derivados de 2-aza-biciclo- [2,2,1] heptano | |
| EA200970510A1 (ru) | Гетеромоноциклическое соединение и его применение | |
| AR086019A1 (es) | COMPUESTOS DE PIRROLO SULFONAMIDA PARA MODULACION DE LA ACTIVIDAD DEL RECEPTOR HUERFANO g RELACIONADO AL RECEPTOR NUCLEAR HUERFANO RAR (RORg, NR1F3) Y PARA EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS Y AUTOINMUNES CRONICAS | |
| RS53156B (en) | N1-PYRAZOLOSPIROKETONES AS ACETYL-COA CARBOXYLASE INHIBITORS | |
| ES2655391T3 (es) | Inhibidores isoindolinona de fosfatidilinositol 3-quinasa | |
| AR049291A1 (es) | Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso | |
| AR078756A1 (es) | Moduladores alostericos positivos (map) | |
| CO6460743A2 (es) | Derivados de 7-aza-espiro[3.5]nonano-7-carboxilatos, su preparación y su aplicación en terapéutica | |
| AR086100A1 (es) | Compuestos de cromenona y composiciones farmaceuticas que los contienen | |
| CO6700836A2 (es) | Métodos y composiciones para tratamiento de cancer en pulmon | |
| ECSP13012980A (es) | Derivados de fenil- o piridinil-etinilo | |
| EA201490726A1 (ru) | Фармацевтические соединения для применения в терапии инфекции clostridium difficile | |
| PE20141553A1 (es) | Compuestos de triazolopiridina como inhibidores de la ped10a | |
| AR073565A1 (es) | Derivados de bencimidazol, procesos de preparacion y composiciones farmaceuticas que los contienen | |
| DOP2014000287A (es) | Compuestos de fenoxietil piperidina | |
| EA201590438A1 (ru) | 2-оксо-2,3-дигидроиндолы для лечения расстройств центральной нервной системы |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |